Londamocitinib (JAK1-IN-7) is a potent and selective Janus kinase 1 (JAK1) inhibitor exhibiting anti-inflammatory properties. It is utilized in research to investigate JAK-STAT signaling pathways in inflammatory and autoimmune disease models, both in cellular assays and preclinical studies.